-

Neurotech Launches “Uncovering MacTel” YouTube Channel to Support Patient Education and Awareness

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc. (the “Company”) announces the launch of YouTube channel - Uncovering MacTel, a new disease education resource that delivers accessible, patient-centered information for individuals affected by Macular Telangiectasia Type 2 (MacTel).

Uncovering MacTel debuts with 16 short videos featuring the experiences of four individuals living with MacTel. Navigating life with a rare eye disease can be challenging. The series explores key moments in the patient’s journey including the onset of symptoms, the path to diagnosis, navigating uncertainty, and offers advice for others impacted by MacTel.

“Uncovering MacTel was created to help patients better understand their condition through the voices of people who have experienced it firsthand,” said Thomas M. Aaberg, Jr., M.D. “By sharing these authentic stories, we aim to help patients feel more informed, empowered, and less alone in their journey.”

Neurotech is committed to increasing disease awareness and ensuring patients and caregivers have access to reliable, easy-to-understand resources. By leveraging digital platforms like YouTube, patients can be reached where they are actively seeking information.

About Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing and commercializing transformative therapies for chronic eye diseases.

About Macular Telangiectasia Type 2 (MacTel)
Macular Telangiectasia Type 2 (MacTel), is a bilateral, neurodegenerative disease in adults with characteristic localized retinal degeneration that causes the gradual loss of cells in the retina, resulting in vision loss and secondary alterations of the retinal vasculature, the network of blood vessels that supplies oxygen and nutrients to the retina.

Contacts

Corporate Contact:
Monique Watson, Chief of Staff
m.watson@neurotechusa.com
508.207.8578

Neurotech Pharmaceuticals, Inc.


Release Versions

Contacts

Corporate Contact:
Monique Watson, Chief of Staff
m.watson@neurotechusa.com
508.207.8578

More News From Neurotech Pharmaceuticals, Inc.

Neurotech Provides Corporate Update on Commercial Progress

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc. (the “Company”) today provided an update on its ongoing transition to a commercial‑stage company following the first anniversary of the FDA’s approval of ENCELTO™ (taroretcel-lwey), the Company’s encapsulated cell‑based gene therapy for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). ENCELTO continues to be integrated into retina practices nationwide, supported by expanding access and established commercial manufa...

Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-Code (J3403) to ENCELTO™, effective October 1, 2025. ENCELTO is approved in the U.S. to treat adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a retinal disease that causes progressive vision loss. J-codes are perma...

Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors. Dr. McDonnell has served as the William Holland Wilmer Professor of Ophthalmology and Director of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine, the largest ophthalmology department in the country, s...
Back to Newsroom